Anzu-cel Phase 3 plan changes as slower melanoma events push Immatics to single 2027 analysis
Immatics reshapes anzu-cel’s Phase 3 trial after slower PFS events, targeting one definitive H1 2027 analysis and a larger survival dataset.
Pharma & Biotech